Discontinuation rates and inter-injection interval for repeated intravesical botulinum toxin type A injections for detrusor overactivity
Objective To report discontinuation rates, inter‐injection interval and complication rates after repeated intravesical botulinum toxin type A for the treatment of detrusor overactivity. Method Patients with urodyamically proven detrusor overactivity who had two or more botulinum toxin type A injecti...
Gespeichert in:
| Veröffentlicht in: | International journal of urology 2014-02, Vol.21 (2), p.175-178 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 178 |
|---|---|
| container_issue | 2 |
| container_start_page | 175 |
| container_title | International journal of urology |
| container_volume | 21 |
| creator | Veeratterapillay, Rajan Harding, Chris Teo, Luke Vasdev, Nikhil Abroaf, Ahmed Dorkin, Trevor J Pickard, Robert S Hasan, Tahseen Thorpe, Andrew C |
| description | Objective
To report discontinuation rates, inter‐injection interval and complication rates after repeated intravesical botulinum toxin type A for the treatment of detrusor overactivity.
Method
Patients with urodyamically proven detrusor overactivity who had two or more botulinum toxin type A injections in the period 2004–2011 at Freeman Hospital, Newcastle Upon Tyne, UK, were considered for the present study. Discontinuation rates, complication rates and interval between botulinum toxin type A treatments were retrospectively analyzed.
Results
Overall, 125 patients (median age 53 years, range 19–83 years) were included in the analysis. The female‐to‐male ratio was 2.4:1 and median follow up was 38 months. A total of 96 patients had idiopathic detrusor overactivity, whereas 29 had neurogenic detrusor overactivity. A total of 667 injections were carried out, with 125 patients receiving two injections, 60 receiving three injections, 28 receiving four injections, 14 receiving five injections, three receiving six injections, three receiving seven injections and two receiving eight injections. The mean interval (±standard deviation) between the first and second injection (n = 125) was 17.6 months (±10.4), between the second and third (n = 60) was 15.7 ± 7.4 months, between the third and fourth (n = 28) was 15.4 ± 8.6 months, and between the fourth and subsequent injections (n = 22) was 11.6 ± 4.5 months. A total of 26% required intermittent catheterization, and 18% developed recurrent urinary tract infections. There was a discontinuation rate of 25% at 60 months.
Conclusion
Repeated botulinum toxin type A injections represent a safe and effective method for managing patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity. We have shown that the inter‐injection interval remains unchanged up to five injections. |
| doi_str_mv | 10.1111/iju.12205 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1492708552</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1492708552</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4225-8f32d1b3812d4e8876e56dff6905af7d55dca66e99a5fc27ddecc51d7599fd7c3</originalsourceid><addsrcrecordid>eNp1kEFPHCEYholpo6v14B9o5qiHUWCGYTgatbs2pm2aGpNeCAsfCdvZYQVm6968tj-zv6R0VvdWLkDe53uS70XohOBzks-FWwznhFLM9tCE1DUtKa7pGzTBgoiyJZweoMMYFxiTipJ2Hx3QqiWC03qCfl-7qH2fXD-o5HxfBJUgFqo3hesThNL1C9BjMv7XqiusD0WAFWRypIJaQ3Q6J3Ofhi6rlkXyT64v0mYFf55_XRY7SxynDaQwxPzwawgqB2uXNu_QW6u6CMcv9xG6_3Dz7WpW3n2e3l5d3pW6ppSVra2oIfO8ATU1tC1vgDXG2kZgpiw3jBmtmgaEUMxqyo0BrRkxnAlhDdfVETrdelfBPw4Qk1zmDqDrVA9-iJLUgnLcMkYzerZFdfAxBrByFdxShY0kWP6rXubq5Vh9Zt-_aIf5EsyOfO06Axdb4KfrYPN_k7z9eP-qLLcTLiZ42k2o8EM2vOJMPnyayu9fp1_YjDzIWfUXYJGirg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1492708552</pqid></control><display><type>article</type><title>Discontinuation rates and inter-injection interval for repeated intravesical botulinum toxin type A injections for detrusor overactivity</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Veeratterapillay, Rajan ; Harding, Chris ; Teo, Luke ; Vasdev, Nikhil ; Abroaf, Ahmed ; Dorkin, Trevor J ; Pickard, Robert S ; Hasan, Tahseen ; Thorpe, Andrew C</creator><creatorcontrib>Veeratterapillay, Rajan ; Harding, Chris ; Teo, Luke ; Vasdev, Nikhil ; Abroaf, Ahmed ; Dorkin, Trevor J ; Pickard, Robert S ; Hasan, Tahseen ; Thorpe, Andrew C</creatorcontrib><description>Objective
To report discontinuation rates, inter‐injection interval and complication rates after repeated intravesical botulinum toxin type A for the treatment of detrusor overactivity.
Method
Patients with urodyamically proven detrusor overactivity who had two or more botulinum toxin type A injections in the period 2004–2011 at Freeman Hospital, Newcastle Upon Tyne, UK, were considered for the present study. Discontinuation rates, complication rates and interval between botulinum toxin type A treatments were retrospectively analyzed.
Results
Overall, 125 patients (median age 53 years, range 19–83 years) were included in the analysis. The female‐to‐male ratio was 2.4:1 and median follow up was 38 months. A total of 96 patients had idiopathic detrusor overactivity, whereas 29 had neurogenic detrusor overactivity. A total of 667 injections were carried out, with 125 patients receiving two injections, 60 receiving three injections, 28 receiving four injections, 14 receiving five injections, three receiving six injections, three receiving seven injections and two receiving eight injections. The mean interval (±standard deviation) between the first and second injection (n = 125) was 17.6 months (±10.4), between the second and third (n = 60) was 15.7 ± 7.4 months, between the third and fourth (n = 28) was 15.4 ± 8.6 months, and between the fourth and subsequent injections (n = 22) was 11.6 ± 4.5 months. A total of 26% required intermittent catheterization, and 18% developed recurrent urinary tract infections. There was a discontinuation rate of 25% at 60 months.
Conclusion
Repeated botulinum toxin type A injections represent a safe and effective method for managing patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity. We have shown that the inter‐injection interval remains unchanged up to five injections.</description><identifier>ISSN: 0919-8172</identifier><identifier>EISSN: 1442-2042</identifier><identifier>DOI: 10.1111/iju.12205</identifier><identifier>PMID: 23819724</identifier><language>eng</language><publisher>Australia: Blackwell Publishing Ltd</publisher><subject>Administration, Intravesical ; Adult ; Aged ; Aged, 80 and over ; botulinum toxin ; Botulinum Toxins, Type A - administration & dosage ; Botulinum Toxins, Type A - adverse effects ; complications ; detrusor overactivity ; Female ; Humans ; Male ; Middle Aged ; Neuromuscular Agents - administration & dosage ; Neuromuscular Agents - adverse effects ; Recurrence ; Retrospective Studies ; Treatment Outcome ; Urinary Bladder, Neurogenic - drug therapy ; Urinary Bladder, Overactive - drug therapy ; Urinary Catheterization ; Urinary Tract Infections - etiology ; Urodynamics - drug effects ; Young Adult</subject><ispartof>International journal of urology, 2014-02, Vol.21 (2), p.175-178</ispartof><rights>2013 The Japanese Urological Association</rights><rights>2013 The Japanese Urological Association.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4225-8f32d1b3812d4e8876e56dff6905af7d55dca66e99a5fc27ddecc51d7599fd7c3</citedby><cites>FETCH-LOGICAL-c4225-8f32d1b3812d4e8876e56dff6905af7d55dca66e99a5fc27ddecc51d7599fd7c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fiju.12205$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fiju.12205$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23819724$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Veeratterapillay, Rajan</creatorcontrib><creatorcontrib>Harding, Chris</creatorcontrib><creatorcontrib>Teo, Luke</creatorcontrib><creatorcontrib>Vasdev, Nikhil</creatorcontrib><creatorcontrib>Abroaf, Ahmed</creatorcontrib><creatorcontrib>Dorkin, Trevor J</creatorcontrib><creatorcontrib>Pickard, Robert S</creatorcontrib><creatorcontrib>Hasan, Tahseen</creatorcontrib><creatorcontrib>Thorpe, Andrew C</creatorcontrib><title>Discontinuation rates and inter-injection interval for repeated intravesical botulinum toxin type A injections for detrusor overactivity</title><title>International journal of urology</title><addtitle>Int J Urol</addtitle><description>Objective
To report discontinuation rates, inter‐injection interval and complication rates after repeated intravesical botulinum toxin type A for the treatment of detrusor overactivity.
Method
Patients with urodyamically proven detrusor overactivity who had two or more botulinum toxin type A injections in the period 2004–2011 at Freeman Hospital, Newcastle Upon Tyne, UK, were considered for the present study. Discontinuation rates, complication rates and interval between botulinum toxin type A treatments were retrospectively analyzed.
Results
Overall, 125 patients (median age 53 years, range 19–83 years) were included in the analysis. The female‐to‐male ratio was 2.4:1 and median follow up was 38 months. A total of 96 patients had idiopathic detrusor overactivity, whereas 29 had neurogenic detrusor overactivity. A total of 667 injections were carried out, with 125 patients receiving two injections, 60 receiving three injections, 28 receiving four injections, 14 receiving five injections, three receiving six injections, three receiving seven injections and two receiving eight injections. The mean interval (±standard deviation) between the first and second injection (n = 125) was 17.6 months (±10.4), between the second and third (n = 60) was 15.7 ± 7.4 months, between the third and fourth (n = 28) was 15.4 ± 8.6 months, and between the fourth and subsequent injections (n = 22) was 11.6 ± 4.5 months. A total of 26% required intermittent catheterization, and 18% developed recurrent urinary tract infections. There was a discontinuation rate of 25% at 60 months.
Conclusion
Repeated botulinum toxin type A injections represent a safe and effective method for managing patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity. We have shown that the inter‐injection interval remains unchanged up to five injections.</description><subject>Administration, Intravesical</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>botulinum toxin</subject><subject>Botulinum Toxins, Type A - administration & dosage</subject><subject>Botulinum Toxins, Type A - adverse effects</subject><subject>complications</subject><subject>detrusor overactivity</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neuromuscular Agents - administration & dosage</subject><subject>Neuromuscular Agents - adverse effects</subject><subject>Recurrence</subject><subject>Retrospective Studies</subject><subject>Treatment Outcome</subject><subject>Urinary Bladder, Neurogenic - drug therapy</subject><subject>Urinary Bladder, Overactive - drug therapy</subject><subject>Urinary Catheterization</subject><subject>Urinary Tract Infections - etiology</subject><subject>Urodynamics - drug effects</subject><subject>Young Adult</subject><issn>0919-8172</issn><issn>1442-2042</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kEFPHCEYholpo6v14B9o5qiHUWCGYTgatbs2pm2aGpNeCAsfCdvZYQVm6968tj-zv6R0VvdWLkDe53uS70XohOBzks-FWwznhFLM9tCE1DUtKa7pGzTBgoiyJZweoMMYFxiTipJ2Hx3QqiWC03qCfl-7qH2fXD-o5HxfBJUgFqo3hesThNL1C9BjMv7XqiusD0WAFWRypIJaQ3Q6J3Ofhi6rlkXyT64v0mYFf55_XRY7SxynDaQwxPzwawgqB2uXNu_QW6u6CMcv9xG6_3Dz7WpW3n2e3l5d3pW6ppSVra2oIfO8ATU1tC1vgDXG2kZgpiw3jBmtmgaEUMxqyo0BrRkxnAlhDdfVETrdelfBPw4Qk1zmDqDrVA9-iJLUgnLcMkYzerZFdfAxBrByFdxShY0kWP6rXubq5Vh9Zt-_aIf5EsyOfO06Axdb4KfrYPN_k7z9eP-qLLcTLiZ42k2o8EM2vOJMPnyayu9fp1_YjDzIWfUXYJGirg</recordid><startdate>201402</startdate><enddate>201402</enddate><creator>Veeratterapillay, Rajan</creator><creator>Harding, Chris</creator><creator>Teo, Luke</creator><creator>Vasdev, Nikhil</creator><creator>Abroaf, Ahmed</creator><creator>Dorkin, Trevor J</creator><creator>Pickard, Robert S</creator><creator>Hasan, Tahseen</creator><creator>Thorpe, Andrew C</creator><general>Blackwell Publishing Ltd</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201402</creationdate><title>Discontinuation rates and inter-injection interval for repeated intravesical botulinum toxin type A injections for detrusor overactivity</title><author>Veeratterapillay, Rajan ; Harding, Chris ; Teo, Luke ; Vasdev, Nikhil ; Abroaf, Ahmed ; Dorkin, Trevor J ; Pickard, Robert S ; Hasan, Tahseen ; Thorpe, Andrew C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4225-8f32d1b3812d4e8876e56dff6905af7d55dca66e99a5fc27ddecc51d7599fd7c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Administration, Intravesical</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>botulinum toxin</topic><topic>Botulinum Toxins, Type A - administration & dosage</topic><topic>Botulinum Toxins, Type A - adverse effects</topic><topic>complications</topic><topic>detrusor overactivity</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neuromuscular Agents - administration & dosage</topic><topic>Neuromuscular Agents - adverse effects</topic><topic>Recurrence</topic><topic>Retrospective Studies</topic><topic>Treatment Outcome</topic><topic>Urinary Bladder, Neurogenic - drug therapy</topic><topic>Urinary Bladder, Overactive - drug therapy</topic><topic>Urinary Catheterization</topic><topic>Urinary Tract Infections - etiology</topic><topic>Urodynamics - drug effects</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Veeratterapillay, Rajan</creatorcontrib><creatorcontrib>Harding, Chris</creatorcontrib><creatorcontrib>Teo, Luke</creatorcontrib><creatorcontrib>Vasdev, Nikhil</creatorcontrib><creatorcontrib>Abroaf, Ahmed</creatorcontrib><creatorcontrib>Dorkin, Trevor J</creatorcontrib><creatorcontrib>Pickard, Robert S</creatorcontrib><creatorcontrib>Hasan, Tahseen</creatorcontrib><creatorcontrib>Thorpe, Andrew C</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of urology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Veeratterapillay, Rajan</au><au>Harding, Chris</au><au>Teo, Luke</au><au>Vasdev, Nikhil</au><au>Abroaf, Ahmed</au><au>Dorkin, Trevor J</au><au>Pickard, Robert S</au><au>Hasan, Tahseen</au><au>Thorpe, Andrew C</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Discontinuation rates and inter-injection interval for repeated intravesical botulinum toxin type A injections for detrusor overactivity</atitle><jtitle>International journal of urology</jtitle><addtitle>Int J Urol</addtitle><date>2014-02</date><risdate>2014</risdate><volume>21</volume><issue>2</issue><spage>175</spage><epage>178</epage><pages>175-178</pages><issn>0919-8172</issn><eissn>1442-2042</eissn><abstract>Objective
To report discontinuation rates, inter‐injection interval and complication rates after repeated intravesical botulinum toxin type A for the treatment of detrusor overactivity.
Method
Patients with urodyamically proven detrusor overactivity who had two or more botulinum toxin type A injections in the period 2004–2011 at Freeman Hospital, Newcastle Upon Tyne, UK, were considered for the present study. Discontinuation rates, complication rates and interval between botulinum toxin type A treatments were retrospectively analyzed.
Results
Overall, 125 patients (median age 53 years, range 19–83 years) were included in the analysis. The female‐to‐male ratio was 2.4:1 and median follow up was 38 months. A total of 96 patients had idiopathic detrusor overactivity, whereas 29 had neurogenic detrusor overactivity. A total of 667 injections were carried out, with 125 patients receiving two injections, 60 receiving three injections, 28 receiving four injections, 14 receiving five injections, three receiving six injections, three receiving seven injections and two receiving eight injections. The mean interval (±standard deviation) between the first and second injection (n = 125) was 17.6 months (±10.4), between the second and third (n = 60) was 15.7 ± 7.4 months, between the third and fourth (n = 28) was 15.4 ± 8.6 months, and between the fourth and subsequent injections (n = 22) was 11.6 ± 4.5 months. A total of 26% required intermittent catheterization, and 18% developed recurrent urinary tract infections. There was a discontinuation rate of 25% at 60 months.
Conclusion
Repeated botulinum toxin type A injections represent a safe and effective method for managing patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity. We have shown that the inter‐injection interval remains unchanged up to five injections.</abstract><cop>Australia</cop><pub>Blackwell Publishing Ltd</pub><pmid>23819724</pmid><doi>10.1111/iju.12205</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0919-8172 |
| ispartof | International journal of urology, 2014-02, Vol.21 (2), p.175-178 |
| issn | 0919-8172 1442-2042 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1492708552 |
| source | MEDLINE; Access via Wiley Online Library |
| subjects | Administration, Intravesical Adult Aged Aged, 80 and over botulinum toxin Botulinum Toxins, Type A - administration & dosage Botulinum Toxins, Type A - adverse effects complications detrusor overactivity Female Humans Male Middle Aged Neuromuscular Agents - administration & dosage Neuromuscular Agents - adverse effects Recurrence Retrospective Studies Treatment Outcome Urinary Bladder, Neurogenic - drug therapy Urinary Bladder, Overactive - drug therapy Urinary Catheterization Urinary Tract Infections - etiology Urodynamics - drug effects Young Adult |
| title | Discontinuation rates and inter-injection interval for repeated intravesical botulinum toxin type A injections for detrusor overactivity |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-22T11%3A57%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Discontinuation%20rates%20and%20inter-injection%20interval%20for%20repeated%20intravesical%20botulinum%20toxin%20type%E2%80%89A%20injections%20for%20detrusor%20overactivity&rft.jtitle=International%20journal%20of%20urology&rft.au=Veeratterapillay,%20Rajan&rft.date=2014-02&rft.volume=21&rft.issue=2&rft.spage=175&rft.epage=178&rft.pages=175-178&rft.issn=0919-8172&rft.eissn=1442-2042&rft_id=info:doi/10.1111/iju.12205&rft_dat=%3Cproquest_cross%3E1492708552%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1492708552&rft_id=info:pmid/23819724&rfr_iscdi=true |